Bruna Rodrigues Dias Assis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bruna Rodrigues Dias Assis has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gisele Assis Castro Goulart
Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Ana Luiza Chaves Maia
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Ana Paula Fernandes
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Eduardo Burgarelli Lages
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Flávia Fonseca Bagno
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Graziella Gomes Rivelli
Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 300
Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies
Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH,
- 18 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 300
Open AccessComprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies
Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH,
- 1 August 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (18) , 1175-1194
Quality Attributes of Ctvad1, A Nanoemulsified Adjuvant for Phase I Clinical Trial of SpiN COVID-19 Vaccine
Aim: To develop, characterize and evaluate an oil/water nanoemulsion with squalene (CTVad1) to be approved as an adjuvant for the SpiN COVID-19 vaccine clinical trials. Materials & methods: Critica... Graphical abstract
- 1 August 2023
- Published by Taylor & Francis in Nanomedicine
- Vol. 18 (18) , 1175-1194
Quality Attributes of Ctvad1, A Nanoemulsified Adjuvant for Phase I Clinical Trial of SpiN COVID-19 Vaccine
Aim: To develop, characterize and evaluate an oil/water nanoemulsion with squalene (CTVad1) to be approved as an adjuvant for the SpiN COVID-19 vaccine clinical trials. Materials & methods: Critica... Graphical abstract
- 22 November 2021
- Published by Taylor & Francis in Nanomedicine
- Vol. 16 (29) , 2565-2568
Nanotechnology in Adjuvants and Vaccine Development: What Should We Know?
- 22 November 2021
- Published by Taylor & Francis in Nanomedicine
- Vol. 16 (29) , 2565-2568
Nanotechnology in Adjuvants and Vaccine Development: What Should We Know?